20 articles
Online portal reveals public preferences for dementia treatments, with safety concerns outweighing efficacy in drug selection decisions.
A Danish double-blind RCT tests a novel at-home electromagnetic field headband against sham for moderate-to-severe depression over 8 weeks.
A new study warns that diabetes medications could confound Alzheimer's biomarker studies, distorting our understanding of the diabetes-dementia link.
Stanford researchers find pioglitazone and liraglutide improve CNS insulin signaling, measured via neuron-derived vesicles in blood.
Tavapadon, a once-daily oral medication, significantly improved motor function in early Parkinson's patients with fewer side effects.
Dopamine agonist pramipexole significantly reduced depression symptoms when added to standard antidepressants in resistant cases.
Novel D1/D5 receptor agonist shows promise for reducing motor fluctuations in Parkinson's patients with fewer side effects.
A phase 2 RCT finds ABvac40, a vaccine targeting vascular amyloid-Ξ²40, is safe and immunogenic in early Alzheimer's patients with no ARIA-E.
Eptinezumab injection plus patient education dramatically reduced migraine frequency in people with chronic migraines and medication overuse.
Nicotinamide riboside prevents moyamoya-like brain vessel blockages by fixing cellular energy production in smooth muscle cells.
Comprehensive review of TSC reveals mTOR inhibitor successes while identifying critical unmet needs in neuropsychiatric care.
A GeneReviews update details how activating MTOR variants cause a rare overgrowth-intellectual disability syndrome, with early rapamycin trials showing promise.
Breakthrough antisense therapy demonstrates sustained benefits for rare genetic form of ALS in extended clinical trial.
A validated UPLC-MS/MS method analyzing 566 plasma samples reveals key patient factors that explain why standard antidepressant doses fail many people.
Researchers built a machine learning imaging pipeline to detect cerebral microhemorrhages and tested SS-31 (elamipretide) in aged hypertensive mice.
A new Cell study reveals the fronto-insular circuit as the key mediator of TMS antidepressant effects, opening the door to optimized treatment.
A randomized pilot study finds PEMF therapy significantly improved fatigue, sleep, depression, and walking capacity in post-COVID-19 patients over 5 weeks.
New research reveals how TSC2 mutations suppress translation of autism and epilepsy genes, offering potential therapeutic targets.
Large FDA database analysis reveals methylphenidate may reduce suicide risk while atomoxetine increases it in pediatric ADHD patients.
New research reveals how melatonin prevents harmful protein aggregation linked to both type 2 diabetes and brain degeneration.
